In most gene therapy studies, a 'corrected' therapeutic gene is inserted into the genome to replace an 'abnormal' disease-causing gene. A vector (ie, a carrier) must be used to deliver the therapeutic gene to the patient's target cells. The most common vectors are viruses, but viral vectors are often toxic or immunogenic and make it difficult to verify successful infection of the targeted cells.
An ideal gene delivery system should be stable, biocompatible, nontoxic, cost-effective, and capable of transferring exogenous, highly anionic genetic materials (ie, DNA, antisense oligodeoxynucleotides [AS-ODNs], short interfering ribonucleic acids [RNAs] ) into tissue-specific sites. A primary goal of gene therapy is to target vectors and the genes of interest efficiently to specific cell types. Recent advances in nanoparticle technology have yielded new types of gene vectors.
Magnetic iron oxide (Fe 3 O 4 ) nanoparticles are considered ideal gene vectors because they are simple to manufacture, have diameters of ,10 nm, are able to absorb a significant amounts of DNA, demonstrate limited cellular toxicity, and can be guided to specific sites via magnets. In addition, to improve biocompatibility, iron oxide nanoparticles can be embedded in various macromolecules, such as polysaccharides and proteins. However, human organs such as liver, spleen, and lymph (among others) are infused with a reticuloendothelial system and have the ability to passively absorb nanoparticles through phagocytosis. Because β-human chorionic gonadotropin (HCG) is expressed only in choriocarcinomas, anti-β-HCG monoclonal antibody were attached to magnetic particles to allow the nanoparticles to target the tissues of interest.
In this study, nanometer-sized dextran-coated iron oxide particles modified with an anti-β-HCG monoclonal antibody were synthesized, and the feasibility of using Fe 3 O 4 -dextran-anti-β-HCG as a gene vector was tested.
Material and methods Materials
All reagents used for nanoparticle synthesis were commercial products. Dextran (40,000 MW; T-40), deoxyribonuclease I (DNase I), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich Corporation (St. Louis, MO). Lipofectamine2000 was purchased from Invitrogen Corporation (Carlsbad, CA). Mouse anti-human β-HCG monoclonal antibody was purchased from Wolwo Biotechnology (Shanghai, China). Goat anti-mouse immunoglobulin G/fluorescein isothiocynate (IgG/FITC) and goat antimouse IgG/horseradish peroxidase (HRP) were purchased from Shiruike Biotechnology (Shanghai, China). DNA marker ΦX174-Hinc II digest was obtained from TaKaRa Corporation (Shiga, Japan). Analytical grade chemicals (ie, FeCl 3 ⋅6H 2 O, and FeCl 2 ⋅4H 2 O) were obtained from local suppliers. All aqueous solutions were prepared using distilled water and filtered through 0.22-mm membranes.
JEG-3 and JAR human choriocarcinoma cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA). RL95-2, Hela, HepG2, and Lovo cell lines were supplied by the cell center of Central South University (Changsha, China).
Female BALB/c nude mice (4 weeks old) were supplied and fed by the animal division of Central South University.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) AS-ODN was synthesized by Shanghai Sangon Biological Engineering Technology and Services Company Ltd (Shanghai, China). The GAPDH AS-ODN sequence was 5′-GAC CTT CAC CAT CTT GTC TA-3′, with a 5′ terminal FITC group including some phosphorothioated nucleotides. Oligonucleotides were diluted to 100 µmol/L and stored at −20°C.
Cell culture studies
JEG-3, JAR, RL95-2, Hela, HepG2, and Lovo cell lines were cultured in Roswell Park Memorial Institute (RPMI) medium (Invitrogen) supplemented with 10% fetal calf serum.
Preparation and physical characterization of magnetic Fe 3 O 4 -dextran-anti-β-HCG nanoparticles Preparation of nanoparticles
Fe 3 O 4 -dextran-anti-β-HCG nanoparticles were prepared as described by Xia et al. 2 Dextran (5 g), FeCl 3 ⋅6H 2 O (0.552 g), and FeCl 2 ⋅4H 2 O (0.45 g) were dispersed in 10 mL water. The mixture was titrated to alkaline by 10 mL of 5 mol/L ammonia and quickly heated to 60°C, with magnetic stirring. After 30 min, the suspension was neutralized with acetic acid. Aggregates were removed by centrifugation for 10 min. The dextran-coated iron oxide nanoparticles were separated from unbound dextran by magnetic separator and eluted with 10 mL sodium acetate (pH 6.5). The dextran-coated iron oxide suspension was oxidized with sodium periodate (NaIO 4 ) with magnetic stirring in the dark at 4°C for 1 h to drive aldehyde termination. The solution was dialyzed while under magnetic stirring. Then, 100 µg mouse anti-human β-HCG monoclonal antibody was mixed with 1 mL aldehyde dextran-coated iron oxide nanoparticle solution. The solution was kept in the dark at 4°C for 24 h and then blocked by 50 µL 10% wt/vol BSA. To improve stability, 1 mol/L sodium borohydride (NaBH 4 ) was added to the compound at 4°C for 3 h and stirred. Finally, the suspension was centrifuged for 20 min at 13,000 rpm, repeated three times. The final product was dispersed in 1 mL sodium perborate (NaBO 3 ) (pH 8.5) and preserved at 4°C.
Morphological determination
The Fe 3 O 4 -dextran-anti-β-HCG nanoparticles solution was titrated with a copper wire. After drying, morphological structure was determined by CM120 transmission electron microscopy (TEM) (Philips, Eindhoven, The Netherlands).
effective diameter determination dextran-coated iron oxide nanoparticles), and anti-β-HCG monoclonal antibody solutions (at 10, 50, 80 100, or 150 µg/mL anti-β-HCG monoclonal antibody) were titrated into the wells (100 µL/well) which were incubated for 1 h at 37°C. Dextrancoated iron oxide nanoparticles served as a control. After washing two times, goat antimouse IgG/HRP (diluted 1:2000) was added into each well and wells were incubated at 37°C for 1 h. Solutions were prepared by addition of 3,3′,5,5′-tetramethylbenzidine peroxidase, for 15-20 min at 37°C, and the reactions were stopped by addition of 2M H 2 SO 4 (50 µL/ well). Optical density (OD) was read at 492 nm immediately after stopping the reaction in an ELX808 Ultra Microplate Reader (Bio-Tek, Winooski, VT). All samples were prepared in triplicate. The percent transfection was calculated as OD anti-β-HCG monoclonal antibody activity of aldehyde or nonaldehyde Fe 3 O 4 -dextran-anti-β-HCG nanoparticle/OD anti-β-HCG monoclonal antibody × 100. 
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Evaluation of Fe 3 O 4 -dextran-anti-β-HCG nanoparticles as gene vectors Preparation of Fe 3 O 4 -dextran-anti-β-hcg-gAPDh As-ODN mixtures
Mouse antihuman β-HCG monoclonal antibody (10 µg) and GAPDH AS-ODN (20 µL in 100 µmol/L) were mixed with 100 µL aldehyde or nonaldehyde dextran-coated iron oxide nanoparticles. Following incubation in the dark at 4°C for 24 h, the mixture was blocked by 5 µL of 10% wt/vol bovine serum albumin (BSA). To improve stability, 1-mol/L NaBH 4 was added to the mixture at 4°C and stirred for 3 h. Finally, the suspension was centrifuged for 20 min at 13,000 rpm, the supernatant removed, and dispersed again with 100 µL NaBO 3 (pH 8.5). This centrifugation and wash step were repeated three times. . Fluorescence intensity was measured using flow cytometry as described.
Distribution of Fe 3 O 4 -dextran-anti-β-hcg nanoparticles in nude mice
Cultured JEG-3 cells were harvested and resuspended in naive RPMI medium at 4-6 × 10 6 cells/mL, and 100 µL were immediately injected into the flank of eight nude mice. When tumor diameter reached ∼8-10 mm, Fe 3 O 4 -dextran-anti-β-HCG nanoparticle solution (0.5 mL/mouse, 1.5 mg/mL Fe 3+ ) was injected into tail veins of eight mice; the hypodermal tumor of four mice (group I) were treated with a 12,000 gauss, 1-cm-diameter magnetic stick, and four mice (group II) were not treated. Dextran-coated iron oxide nanoparticle solution (0.5 mL/mouse, 1.5 mg/mL Fe 3+ ) was also injected to four mice (group III) through the tail vein. After 30 min, 100 mg of tissue was harvested from heart, liver, spleen, lung, kidney, and choriocarcinoma hypodermal tumors of all mice and digested (nitric acid:perchloric acid, 4:1). Iron content was measured by atomic absorption using a Spectra-30 Photometer.
Statistical analysis
Statistical significance was assessed using Student's t-test or analysis of variance (ANOVA) (one-way ANOVA followed by Dunnett's test) using SAS (SAS Institute, Cary, NC). Differences between means were considered significant at P , 0.05. Indirect immunofluorescence assay for 
Results
Morphology and diameter of Fe 3 O 4 -dextran-anti-β-hcg nanoparticles
Efficiency of Fe 3 O 4 -dextran-anti-β-hcg nanoparticle as gene vector
The fluorescence intensity of group IV in JEG-3 cells is higher than that of groups I, II, III, and V (P , 0.05) ( Table 3 ), indicating that Fe 3 O 4 -dextran-anti-β-HCG nanoparticles are effective as a gene vector. Interestingly, the efficiency of gene transfection using Fe 3 O 4 -dextran-anti-β-HCG nanoparticles is higher than that observed using liposomes (P , 0.05).
Absorption of Fe 3 O 4 -dextran-anti-β-hcg-gAPDh As-ODN in different cells
The fluorescence intensity in JEG-3 and JAR cells is clearly higher than that observed in RL95-2, Hela, HepG2, and Lovo (P , 0.05) ( 
Distribution of Fe 3 O 4 -dextran-anti-β-hcg nanoparticles in nude mice
In groups I and II, iron content in choriocarcinoma hypodermal tumors was highest in heart, liver, spleen, lung, and kidney (P , 0.05). At the same time, it was found that Fe 3+ content in choriocarcinoma hypodermal tumors of group I was higher than that of group II (P , 0.05). In group III, the iron content in choriocarcinoma hypodermal tumors is less than that in liver or spleen (P , 0.05). These results indicate that when modified submit your manuscript | www.dovepress.com
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Jingting et al by β-HCG monoclonal antibody, Fe 3 O 4 nanoparticles are able to target choriocarcinoma tumors and that magnetic fields can strengthen the targeting efficiency (Table 5 ).
Discussion
Gene therapy is the insertion of genes into an individual's cells and tissues to treat a disease. For hereditary diseases, the defective mutant allele is replaced with a functional allele. Antisense therapy is not strictly a form of gene therapy, but it is a genetically mediated therapy and is often used together with other methods. Using AS-ODNs to downregulate specific gene products requires oligonucleotides to enter cells and hybridize to the target messenger RNA present in the cytoplasm and/or nucleus. 3 Nevertheless, the poor ability of oligonucleotides to cross the cell membrane and the degradation of oligonucleotides by DNase I greatly limit their potency. Therefore, it is necessary to identify a safe, effective, and stable gene vector. 4, 5 The development of nanoparticle technology provides a new type of gene vector. Nanoparticles possess several advantages as gene vectors: 6 1) they are not biologic materials, so they should not induce immune responses; 2) unlike viral carriers, they have limited genotoxicity and cytotoxicity; 3) they can mediate the insertion of foreign genes into DNA of host chromosomes, and as a result, foreign genes are stably expressed; 4) they can protect foreign genes from complement and host enzymes; and 5) they can counteract or kill some viruses. With these advantages, nanoparticles have promise as gene vectors. The feasibility and superiority of Fe 3 O 4 -dextran-anti-β-HCG nanoparticles as gene vector are discussed in the next section.
Preparation and characterization of Fe 3 O 4 -dextran-anti-β-hcg nanoparticles
Dextran, FeCl 3 , and FeCl 2 precipitate together under alkaline conditions. As a result, nanometer-sized dextran-coated iron oxide particles may be synthesized. The surface of dextran contains many hydroxyl groups. Once oxidized by NaIO 4 , these hydroxyl groups can transform to aldehyde 
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Preparation and characterization of magnetic nanoparticles groups. According to the Schiff reaction, aldehyde dextrancoated iron oxide nanoparticles combine with anti-β-HCG monoclonal antibody and form stable products. BSA is then used to block the surplus hydroxyl groups ( Figure 5 ). In this study, Fe 3 O 4 -dextran-anti-β-HCG nanoparticles with an average diameter of 75.5 nm were synthesized. The results indicate that the magnetic nanoparticles, which have a diameter of ,100 nm, can take therapeutic genes into host cells. Moreover, nanoparticles can be targeted to specific tissues when guided by a magnet. 7 At the same time, dextran-coated Fe 3 O 4 -dextran-anti-β-HCG nanoparticles can escape from the reticuloendothelial system and disperse in a fluid medium. These characteristics can help nanoparticles prolong the half-life, and this kind of stability also suggests 
Biocompatibility of Fe 3 O 4 -dextrananti-β-hcg nanoparticles
Having a safe gene carrier is very important for gene therapy. Studies have confirmed that iron-containing fluids have favorable biocompatibility. Unutilized iron is discharged by skin, gallbladder, and kidney. 8, 9 The biocompatibility of Fe 3 O 4 particles is improved further with a dextran coating.
In this study, it was found that when the concentration of Fe 3+ is ,37.5 µg/mL, nanoparticles were not toxic to choriocarcinoma cells.
Immunoreactivity of Fe 3 O 4 -dextrananti-β-hcg nanoparticles
It is important that the process of combining dextran-coated iron oxide nanoparticles with anti-β-HCG monoclonal antibody preserves the antibody activity. In this study, it was found that the transfection efficiency of anti-β-HCG monoclonal antibody activity in aldehyde Fe 3 O 4 -dextran-anti-β-HCG nanoparticle is higher than 85%, whereas the transfection efficiency of anti-β-HCG monoclonal antibody activity in nonaldehyde Fe 3 O 4 -dextran-anti-β-HCG nanoparticle is about 13%. This indicates that nonaldehyde dextran-coated iron oxide nanoparticles do not effectively bind to antibodies, although it is feasible for aldehyde dextran coat iron oxide nanoparticles to preserve antibody activity. To study the interactions between easily influence its zeta potential. In acidic conditions the zeta potential can become positive, making it possible for Fe 3 O 4 -dextran nanoparticles to bind with the negative surface potential of DNA. In alkaline conditions nanoparticle zeta potential can become negative, making it highly unfavorable for the nanoparticles to bind with DNA. 10 The pH of extracellular fluid in human beings is 7.35-7.45, an alkaline environment, so it is unlikely for Fe 3 O 4 -dextran nanoparticles to combine with naked DNA. In this study, DNA was linked with Fe 3 O 4 -dextran-anti-β-HCG nanoparticles using an oxidation-reduction reaction. Electrophoretic analysis indicated that after being oxidized by NaIO 4 , Fe 3 O 4 -dextran-anti-β-HCG nanoparticles obtain the ability to bind with DNA. The principle is similar to that of combining Fe 3 O 4 -dextran nanoparticles with anti-β-HCG monoclonal antibody. Using flow cytometry, it was also found that Fe 3 O 4 -dextran-anti-β-HCG nanoparticles can help DNA insert into JEG-3 cells. Moreover, the transfection efficiency of Fe 3 O 4 -dextran-anti-β-HCG nanoparticles is higher than that for liposomes. This may be due to the small, narrow diameter of Fe 3 O 4 -dextran-anti-β-HCG nanoparticles, which provides a large specific surface area to bind DNA.
If DNA is digested by nucleases, the transfection efficiency will be reduced. 11 As a gene vector, nanoparticles have the advantage of protecting DNA from nucleases. 12 Chavany et al 13 reported that poly(alkyl cyanoacrylate) nanoparticles can protect oligonucleotides from nucleases. Cui and Mumper 14 discovered that free 'naked' plasmid DNA (pDNA) was completely digested by serum nucleases, while the entrapped pDNA remained intact. Moreover, in vitro transfection studies in HepG2 cells showed that pullulan-coated nanoparticles resulted in enhanced luciferase expression, compared with both pDNA alone and uncoated nanoparticles. Nakada et al 15 found that nanoparticles could partially protect pdT16 against degradation in the plasma and in the liver 5 min after administration, whereas free oligonucleotide was totally degraded. In this study, it was also found that Fe 3 O 4 -dextran-anti-β-HCG nanoparticles protect GAPDH AS-ODN from DNase I. This result is similar to research findings by Xiang et al. 16, 17 Rhaese et al 18 reported that the reason for the protection is that DNA is surrounded by nanoparticles.
Target of Fe 3 O 4 -dextran-anti-β-hcg nanoparticle
Developing targeted gene vectors is a very active area of research in the field of genes therapy. In the absence of tissue-specific targeting, therapeutic genes will spread to all organs through blood flow. This will not only reduce the drug concentrations in diseased organs, but also cause side effects. Researchers are, therefore, doing their best to increase drug concentrations in diseased organs, while decreasing the drug concentrations in other organs. As a gene vector, nanoparticles are of interest because they can impact distribution of DNA in the body due to targeting capabilities. Nanoparticle targeting can be divided into passive targeting and active targeting. 6 In passive targeting, nanoparticles are taken into the reticuloendothelial system, such as the liver, spleen, and lymph, which is beneficial to diseases of the reticuloendothelial system. However, when being used to treat tumors, nanoparticles are expected to assemble in the tumor itself, so the need to obtain active targeting becomes even more important.
Active targeting is subdivided into physical, chemical, and biological targeting. Physical and chemical targeting are realized according to the pH, temperature, and magnetism of the nanoparticle, whereas biological targeting is realized according to the antigen and acceptor on the surface of nanoparticle.
To target choriocarcinomas, it is important to reduce the amount of nanoparticle that is absorbed by the reticuloendothelial system. Fe 3 O 4 -dextran-anti-β-HCG nanoparticles that possess magnetic-and immune-targeting capabilities were prepared. To demonstrate nanoparticle targeting, the absorption of Fe 3 O 4 -dextran-anti-β-HCG-GAPDH AS-ODN in different cells was tested. The transfection efficiency of Fe 3 O 4 -dextran-anti-β-HCG nanoparticles in choriocarcinoma JEG-3 and JAR cells was found to be much higher than that in RL95-2, Hela, HepG2, and Lovo cells. This indicates that anti-β-HCG monoclonal antibody in Fe 3 O 4 -dextran-anti-β-HCG nanoparticles combined specifically with β-HCG antigen in choriocarcinoma cells. In other words, these nanoparticles have characteristics of biological targeting. However, it was also found that when using magnetic and immune targeting together, Fe 3 O 4 -dextran-anti-β-HCG nanoparticles are absorbed into the target reticuloendothelial system and assemble in the choriocarcinoma tumor. Furthermore, the combined effect of magnetic and immune targeting is stronger than that of magnetic targeting or immune targeting alone.
Conclusion
In summary, Fe 3 O 4 -dextran-anti-β-HCG nanoparticles represent an appropriate vector for gene therapy and demonstrate strong resistance to degradation. They combine high transfection efficiency with good biocompatibility and low cytotoxicity. Because they can be targeted using magnetic and antibody recognition mechanisms, they offer the possibility for additional targeting strategies beyond those currently in use.
